KeyBanc upgraded Sotera Health to Overweight from Sector Weight with a $24 price target. The investor conversation can finally shift back toward the company’s positive underlying fundamentals following the settlement of its ethylene oxide claims in Willowbrook, Illinois, the analyst tells investors in a research note. The firm is confident in Sotera’s revenue growth outlook, saying it could benefit from improving medical device volumes as well as investments to support industry capacity. The stock’s valuation discount could narrow over time as investors become more comfortable around remaining overhangs, contends KeyBanc.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SHC:
- Sotera Health Announces Jon Lyons as New Senior Vice President and Chief Financial Officer
- Sotera Health’s settlement in Illinois a positive for stock, says KeyBanc
- Sotera Health Finalizes Settlement of Ethylene Oxide Litigation in Illinois
- Sotera Health finalizes settlement of ethylene oxide litigation in Illinois
- Sotera Health to Present at the 2023 RBC Capital Markets Global Healthcare Conference